Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Jared Fink

Jared Fink Jared Fink is the firm’s pharmacovigilance specialist. He is a graduate of the College of Wooster and has a strong background in scientific research and writing. His full biography is here.

Posts by Jared Fink

2011 – Low gestational age linked to SSRI exposure, not maternal depression

Posted in SSRI Birth Defects

Titled “Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment.”, an article by A.L. Salisbury and a team from the Warren Alpert Medical School of Brown University, appearing in the December, 2011 edition of Depression and Anxiety, further explores the link between selective serotonin reuptake inhibitor drugs… Continue Reading

Neurological function adversely affected by maternal SSRIs

Posted in SSRI Birth Defects

In May, 2013, N.K. de Vries published an article titled “Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study.” in the medical journal PLoS One.  This Dutch research team explored poor neonatal outcomes linked to selective serotonin reuptake inhibitor drugs (SSRIs). de Vries et… Continue Reading

2011 – Heart development affected by maternal SSRI use

Posted in SSRI Birth Defects

Published in the July, 2011 edition of Pediatric Research, a study by D. Rurak and a team from The University of British Columbia (Vancouver) titled “Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure.” examined the relationship between selective serotonin reuptake inhibitor drugs… Continue Reading

Study shows SSRIs affect fetal neurodevelopment

Posted in SSRI Birth Defects

From The Netherlands, a team of medical researchers led by E.J. Mulder published a study titled “Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus.” in the September, 2011 edition of Neuropsychopharmacology examining the relationship between exposure to selective serotonin reuptake inhibitor drugs (SSRIs) and adverse birth outcomes. The team states “The aim… Continue Reading

Autism, poor neurodevelopment linked to SSRIs in pregnancy

Posted in SSRI Birth Defects

An article titled “SSRI antidepressants: altered psychomotor development following exposure in utero?” that appeared in the February, 2013 edition of Prescrire International examines additional risks of prenatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs).  To be clear, a number of other studies have linked adverse birth outcomes linked to SSRI exposure in years passed…. Continue Reading

2013 – Researchers show that SSRIs (not maternal depression) cause poor neonatal outcomes

Posted in SSRI Birth Defects

Last summer, a team of researchers from University of British Columbia (Vancouver) led by G.E. Hanley published a study titled “Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.” in Early Human Development.  This study examined the relationship between poor early childhood development and gestational exposure to selective serotonin… Continue Reading

Prozac, Pazil, Zoloft, Celexa linked to Persistent Pulmonary Hypertension of the Newborn (PPHN)

Posted in Celexa Birth Defects, Effexor Birth Defects, Paxil Birth Defects, Prozac Birth Defects, SSRI Birth Defects, Zoloft Birth Defects

Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth. Galbally et al. (2012) writes “Persistent… Continue Reading

2006 – Persistent Pulmonary Hypertension Linked to SSRIs in Pregnancy

Posted in SSRI Birth Defects

A team of researchers from Sydney, Australia (led by M.P. Austin) published an article in a December, 2006 edition of Psychological Medicine titled “To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects.” that attempted to clarify negative consequences of prenatal exposure to SSRI drugs like Prozac, Paxil, and… Continue Reading

More research links poor development with SSRI exposure

Posted in SSRI Birth Defects

An article in Early Human Development (February, 2013) by M.V. Smith et al. titled “Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.”, from The Yale School of Medicine delves further into the link between prenatal SSRI exposure and adverse birth outcomes.  Selective serotonin reuptake inhibitor drugs (SSRIs) are… Continue Reading

Huge birth defect increase with Depacon / Depakene / Depakote in pregnancy

Posted in Depacon / Depakene / Depakote

Today, I came across an article from the February, 2012 edition of The Australian and New Zealand Journal of Obstetrics and Gynecology published by F.J. Vajda and a team of researchers at University of Melbourne (Australia).  In their piece, titled “The prescribing of antiepileptic drugs for pregnant Australian women.” Vajda et al. explore further the… Continue Reading

JAMA: Autism risk 500% increased with Depakote, Depakene, and Depacon in utero

Posted in Depacon / Depakene / Depakote

In the April, 2013 edition of JAMA, an article titled “Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.” from a Danish team led by J. Christensen evaluated the risks of prenatal exposure to the antiepileptic Depacon.  Because Abbott Laboratories, the manufacturer of this drug, failed time and again to warn of… Continue Reading

Birth defects at significantly higher rate with Depacon, Depakene

Posted in Depacon / Depakene / Depakote

Titled “Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.”, an article by J. Morrow and a team from Belfast (UK) published in the February, 2006 edition of Journal of Neurology, Neurosurgery, and Psychiatry aimed to “assess the relative risk of major congenital malformation (MCM) from in… Continue Reading

2014 – Increased risk for birth defects seen with Depakote exposure

Posted in Depacon / Depakene / Depakote

In July, 2014, a team of Norwegian researchers led by K.O. Nakken published an article in Tidsskr Nor Laegeforen titled “Antiepileptic drugs and congenital malformations”, evaluating the consequences of prenatal exposure to epilepsy drugs containing sodium valproate, such as Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.).  To-date, dozens of studies have demonstrated that a dramatically-increased… Continue Reading

2008 – Epilepsy drugs with valproate linked to higher risk of birth defects, low IQ

Posted in Depacon / Depakene / Depakote

From Stockholm, Sweden, a 2008 piece titled “Teratogenic effects of antiepileptic drugs.” and appearing in the medical journal, Seizure, by T. Tomson et al. yet again demonstrates the postnatal risks of prenatal exposure to epilepsy drugs containing sodium valproate such as Depakote, Depakene, and Depacon (Abbott Laboratories, Inc.). Here, it is stated that “The use… Continue Reading

Harvard: Depacon, Depakote, Depakene linked to poor birth outcomes

Posted in Depacon / Depakene / Depakote

In recent years, a number of studies have shown that prenatal exposure to sodium valproate (the active ingredient in epilepsy drugs Depacon, Depakene, and Depakote) is linked to increased risk for birth defects.  Here, I’ll summarize one such study, titled “Differential effects of antiepileptic drugs on neonatal outcomes.” by P.B. Pennell and a team from… Continue Reading

1992 – Japan finds Depakote, Depakene, Depacon associated with higher birth defect rate

Posted in Depacon / Depakene / Depakote

Titled “Malformation in infants of mothers with epilepsy receiving antiepileptic drugs.”, a piece of Japanese medical research by S. Kaneko et al. published in April, 1992 helps show just how long it has been known that prenatal exposure to epilepsy drugs containing valproate is linked to birth defects.  Depacon, Depakote, and Depakene are top examples… Continue Reading

Finnish Research Shows: Depakote Linked to Birth Defects

Posted in Depacon / Depakene / Depakote

In May, 2013, a Finnish team of medical researchers led by M. Aratma published a study in Drug Safety titled “Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland.”.  This piece further elucidated the link between prenatal exposure to antiepileptic drugs such as… Continue Reading

2003 – AEDs with valproate linked to neurological birth defects

Posted in Depacon / Depakene / Depakote

In a 2003 edition of Epilepsia, a piece titled “Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation.” by M.S. Yerby and a team from North Pacific Epilepsy Research in Portland, Oregon demonstrated that a child’s in utero exposure to maternal antiepileptic drugs (particularly those containing valproate – Depakote, Depakene,… Continue Reading

2013 – Neurological and heart defects linked to Depakote

Posted in Depacon / Depakene / Depakote

A piece by medical researchers led by F.J. Vajda published in Acta Neurol Scand. (October, 2013), titled “Associations between particular types of fetal malformation and antiepileptic drug exposure in utero.” lives up to its title and provides more insight into the link between in utero exposure to epilepsy medication (Depacon, Depakene, and Depakote by Abbott… Continue Reading

2009 – More research links Depakote (and other AEDs) to birth defects

Posted in Depacon / Depakene / Depakote

Appearing in the July-August, 2009 edition of the Spanish medical journal, Neurologia, a piece titled “Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years” by M. Martinez Ferri et al. aimed to “study the incidence of major congenital malformations (MCM) /and/or fetal-perinatal death (MFP) and determine his relationship… Continue Reading

2002 – Research shows AED exposure lifts rate of neonatal morbidity and birth defects

Posted in Depacon / Depakene / Depakote

In April, 2002, a team of medical researchers from Aberdeen (UK) led by J.C. Dean published a study titled “Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth.” in Journal of Medical Genetics investigating the link between neonatal and later childhood morbidity “in children exposed to antiepileptic drugs [AEDs] in utero.”… Continue Reading

Depakote, other AEDs again linked to birth defects

Posted in Depacon / Depakene / Depakote

An article appearing in the May, 2010 edition of Epilepsia titled “The teratogenic risk of antiepileptic drug polytherapy.” by F.J. Vajda and a team from Royal Melbourne Hospital and University of  Melbourne (Australia) further explores the connection between antiepileptic drugs containing sodium valproate such as Depacon, Depakene, and Depakote and increased risk for congenital malformations…. Continue Reading

2011 – Depacon, Depakene, Depakote exposure linked to poor language skills

Posted in Depacon / Depakene / Depakote

In February, 2011, C. Nadebaum and a British research team published a piece in Neurology titled “Language skills of school-aged children prenatally exposed to antiepileptic drugs.” that provides important insight into the connection between antiepileptic drugs containing sodium valproate (Depacon, Depakene, and Depakote) and birth defects. Nadebaum et al. (2011) state “Fetal exposure to some… Continue Reading

1992 – Study links Depakote and birth defects

Posted in Depacon / Depakene / Depakote

Back in 1992, a French research team led by C. Dravet published a piece in Neurology titled “Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study.” that illuminated risks of prenatal exposure to anti-seizure drugs Depacon, Depakene, and Depakote (Abbott Laboratories).  Since, the US FDA has warned of… Continue Reading